U.S. patent number 3,862,302 [Application Number 05/186,473] was granted by the patent office on 1975-01-21 for pelletized pregnancy test reagents.
This patent grant is currently assigned to Akzona Incorporated. Invention is credited to Stuart Michael Bauer, John Brownlee, Bastiaan Cornelis Goverde, Richard Thompson Price.
United States Patent |
3,862,302 |
Price , et al. |
January 21, 1975 |
PELLETIZED PREGNANCY TEST REAGENTS
Abstract
Pelletized analytical and immunological reagents are prepared in
a stable accurate form containing predetermined and pretested
measured amounts of substances capable of participating in
analytical and immunological reactions, such as pregnancy tests, by
forming these reagents into frozen and freeze-dried beads or
spheres; a set of these pellets comprising an antiserum and an
antigen is placed in a test vessel and moistened with the liquid to
be tested and then allowed to stand until agglutination or
precipitin reaction does or does not occur.
Inventors: |
Price; Richard Thompson
(Verona, NJ), Bauer; Stuart Michael (Parsippany, NJ),
Brownlee; John (West Seneca, NY), Goverde; Bastiaan
Cornelis (Oss, NL) |
Assignee: |
Akzona Incorporated (Asheville,
NC)
|
Family
ID: |
25199790 |
Appl.
No.: |
05/186,473 |
Filed: |
October 4, 1971 |
Related U.S. Patent Documents
|
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
Issue Date |
|
|
808803 |
Mar 20, 1969 |
3655838 |
Apr 11, 1972 |
|
|
Current U.S.
Class: |
436/521; 34/92;
436/805; 436/814; 436/826; 424/533; 436/810; 436/818; 422/920 |
Current CPC
Class: |
B01L
3/0203 (20130101); B01J 2/06 (20130101); F25C
1/00 (20130101); G01N 33/76 (20130101); Y10S
436/818 (20130101); Y10S 436/805 (20130101); Y10S
435/963 (20130101); Y10S 436/81 (20130101); Y10S
436/826 (20130101); Y10S 436/814 (20130101) |
Current International
Class: |
B01J
2/06 (20060101); F25C 1/00 (20060101); B01J
2/02 (20060101); B01L 3/02 (20060101); G01N
33/74 (20060101); G01N 33/76 (20060101); F26b
005/06 (); G01n 001/00 (); G01n 033/16 () |
Field of
Search: |
;424/3,11,12,13,101
;264/13,14 ;34/92 ;62/66 |
References Cited
[Referenced By]
U.S. Patent Documents
Other References
Babson, reprint AJCP, Vol. 32, July 1959, pp. 6-9. .
Sidoti, AJMT, Vol. 25, Sept.-Oct., 1959, pp. 339, 340. .
Drug & Cos. Ind., Vol, 52, Feb. 1943 pp. 197, 199. .
Wagman, Applied Microbiology, Vol. 11, May, 1963 pp.
244-248..
|
Primary Examiner: Meyers; Albert T.
Assistant Examiner: Fagelson; A. P.
Attorney, Agent or Firm: Weisberger; Hugo E.
Parent Case Text
CROSS-REFERENCE TO RELATED APPLICATION
This application is a division of application Ser. No. 808,803,
filed 3/20/69, now U.S. Pat. No. 3,655,838, issued Apr. 11, 1972.
Claims
What is claimed is:
1. A pregnancy test reagent adapted for detecting the presence of
human chorionic gonadotropin in urine consisting essentially of a
stable frozen and freeze-dried pellet containing a predetermined
immunologically effective amount for test purposes of a dried
aqueous suspension of sheep erythrocytes sensitized with human
chorionic gonadotropin.
2. A pregnancy test reagent adapted for detecting the presence of
human chorionic gonadotropin in urine consisting essentially of a
stable frozen and freeze-dried pellet containing a predetermined
immunologically effective amount for test purposes of human
chorionic gonadotropin antiserum together with an effective amount
of a phosphate buffer.
Description
BACKGROUND OF THE INVENTION
The present invention relates to novel pelletized reagents, test
methods, and apparatus for performing in-vitro analytical and
immunological reactions, and particularly diagnostic tests
therewith.
The analytical and immunological tests with which the present
invention is concerned are most commonly laboratory tests which
have as their objective the determination of the presence or
absence of antigens or antibodies or enzymes in body fluids as an
aid in the diagnosis of certain physiological or pathological
conditions in humans and animals. Depending upon the particular
combination of reagents and test liquid employed, the reaction may
result in the formation of a precipitate in which case it is known
as a precipitin reaction. Where the reaction is between substances
distributed in a liquid medium, at least one of which substances is
a solid which becomes agglomerated, the reaction is known as an
agglutination reaction. The formation of the precipitate, or the
agglutination or inhibition of agglutination of specially-treated
particles is manifested visually in the way the precipitate forms
or the particles arrange themselves following reaction.
The immunological tests, which may include, for example, tests for
blood group type, pregnancy, and similar phenomena, are customarily
performed with reagents such as, for example, a suspension of
sensitized erythrocytes, and a solution of suitable antiserum,
dispensed into a test vial from a dropper. Even though the
suspension of erythrocytes may have been titered very carefully the
use of vials and droppers is not only expensive, but is likely to
result in questionable findings because of the limitations in the
accuracy of ordinary droppers. Such droppers are usually
uncalibrated, and although the accuracy of the drop size is of
great importance, such accuracy is rarely attained and the size of
the drops is variable and undependable.
In view of the shortcomings of the vial-dropper test methods, it
has been proposed in the prior art to carry out agglutination
reactions by depositing an accurately measured drop of a reagent
onto a slide or cardboard supporting surface and allowing the drop
to be dried, whereupon the test liquid can subsequently be
deposited thereon to observe the results. Methods of this type are
also subject to inaccuracies in the application of the reagents as
well as the observations made.
It is also frequently necessary for immunological reagents, such as
sensitized erythrocytes, or sensitive protein materials, to be
preserved by refrigeration. This necessarily involves the presence
of special refrigeration equipment and is space-consuming and also
time-consuming because of the problem of transferring refrigerated
solutions. Efforts have been made to overcome the limitations of
the vial-dropper test methods, and the slide type methods, by
subjecting reagents, which may be incompatible with each other in
the presence of moisture, to freezing in successive layers in a
container and thereafter freeze-drying the frozen strata, and a
method of this type is described in U.S. Pat. No. 3,269,905.
However, such a procedure requires special apparatus and technical
knowledge and is expensive and time-consuming to carry out.
GENERAL DESCRIPTION OF THE INVENTION
A principal object of the present invention is to provide in a
single container, all the necessary analytical reagents for
diagnostic tests of the types previously described in a pelletized
form in which they are stable, accurate in unit content, and
completely non-reactive until they are contacted by the liquid to
be tested. Another object of the invention is to provide a method
for the manufacture of pelletized analytical, immunological, or
diagnostic reagents which is inexpensive and practical and which
does not require special elaborate equipment but which may be
carried out conveniently for commercial purposes on a large scale.
Still another object is to make the reagents for diagnostic tests
available in a convenient form while at the same time insuring the
accuracy of the amounts of reagents present to provide dependable
test results. Still another object is to provide a method that
permits two or more otherwise incompatible substances to be
freeze-dried in a single container, while avoiding premature
reaction which might come about in the presence of moisture. A
further objective is to provide a person performing a diagnostic
test with a simple container device in which the reagents are
present in pelletized form so that the test results can be visually
observed.
PELLETIZED REAGENTS
In accordance with a first aspect of the present invention, there
are provided novel dry solid stable pelletized analytical,
diagnostic, and immunological reagents in the form of beads or
small spheres, each furnishing a predetermined and accurately
measured quantity of the reagent. Even though the reagents from
which the pellets are prepared are reactive and may even be
mutually incompatible, the pellets themselves have the advantage
that they are stable and may be present together in a common
container for an indefinite period of time without interaction.
However, the reagents in the pellets are readily reconstituted and
made ready for an analytical, immunological or diagnostic test by
the simple addition thereto of the liquid to be tested.
The composition, preparation and use of the pelletized reagents of
the invention will be specifically illustrated with respect to
reagents for an immunological or diagnostic test for detecting the
presence of human chorionic gonadotropic (HCG) in urine, which test
is utilized in the diagnosis of pregnancy.
However, it will be readily understood by those skilled in this art
that the principles of the invention are not to be regarded as
limited thereto, but may be extended to the preparation and use of
a wide range of pelletized analytical, immunological, and
diagnostic reagents, and to a wide variety of tests which may
employ one or a multiplicity of different pelletized reagents.
Furthermore, auxiliary substances, such as buffers, may also be
pelletized in accordance with the invention and may be utilized in
dry stable form in conjunction with one or more diagnostic test
reagent pellets.
The process of preparation of the pelletized reagents of the
invention broadly comprises the steps of:
a. forming an aqueous solution or suspension of the reagent having
a predetermined concentration;
b. forming an accurately measured or calibrated, free-falling drop
of said solution or suspension;
c. allowing said drop to fall through a body of a water-immiscible
liquid having a density less than that of water and having a
temperature gradient ranging from approximately ambient at its
upper surface to at most a temperature below the freezing point of
the solution being frozen at the lower portion of the column,
thereby freezing said drops to frozen pellets or beads; and
d. collecting the frozen pellets containing a predetermined
quantity of the reagent at the bottom of said body of liquid. The
pellets may then be dried by any suitable method, but freeze-drying
is preferred.
The method of preparation of the pellets of the invention will be
better understood by reference to the accompanying drawings, in
which FIG. 1 depicts in diagrammatic form a system for the
formation of drops of reagent and the freezing thereof to solid
stable pellets.
Referring to FIG. 1, an aqueous solution or suspension containing a
known concentration of the reagent is first prepared.
Advantageously there is incorporated into the solution or
suspension a suitable quantity of an inert matrix-producing
substance or bulking agent, which aids in giving body to the
freeze-dried pellet. Examples of suitable bulking agents include
sugars, such as sucrose, mannose, lactose and mannitol,
proteinaceous materials, such as serum protein, lactalbumin
hydrolysate, and casein hydrolysate.
The reagent solution or suspension is pumped from its storage
vessel 1 through a flexible conduit 2, which may be made of
plastic, for example, transparent polyethylene tubing, by means of
a proportioning pump 3. This is preferably a pulsating type pump
which compresses the flexible tubing by means of rollers, thereby
measuring a predetermined amount of solution per unit time. To form
accurate drops, a pump which delivers about 2.0 ml per minute is
used. From the pump 3 the solution flows through a pulse suppressor
4 so that a nearly uniform flow is maintained. Thence the solution
passes to a special type of dropping pipet 5 which discharges a
predetermined, accurately measured amount in the form of a drop.
Such a drop may contain, for example, from about 0.025 to about
0.07 ml. For HCG antiserum and antigen solutions precisely 0.05 ml
is chosen, since this provides frozen pellets of suitable size for
testing purposes.
The pipette 5 is positioned at a suitable height above the surface
of a body of water-immiscible liquid 6 which is held in a container
7, and in which the drop is frozen. The pipet is at such a height
above the level of the water-immiscible liquid that splashing is
prevented while at the same time the height allows for a free fall
of the drop which results in proper drop size and formation of true
spherical shape, either before or after entry into the
water-immiscible liquid. In order to maintain the height from which
the drop falls to prevent drop distortion and splash, a suction
tube 8 is placed at an appropriate level. As the hexane is
displaced by the aqueous volume introduced as drops this suction
line pulls off excess hexane and thereby maintains a constant
level.
The water-immiscible liquid used for freezing may be a liquid
hydrocarbon or a liquid halogenated hydrocarbon, or mixtures
thereof. Examples of suitable liquids include hexane, carbon
disulfide, chloroform, heptane, iso-octane, or toluene, as well as
mixtures such as hexane-chloroform or benzene-hexane. These
mixtures are designed so that they will always have a density less
than water. For example, hexane has a specific gravity of 0.6593 at
20.degree./4.degree.C. The specific gravity can be adjusted to any
desired level by blending with the hexane another liquid such as
carbon tetrachloride, in order to maintain a controlled rate of
fall of the drop. The rate of fall is advantageously of the order
of about 1 foot per 2 seconds, depending upon the length of the
liquid column. The longer the column, the faster the rate of fall
which can be maintained.
The body of freezing liquid is maintained with a temperature
gradient which ranges from near ambient at its upper surface and
diminishes in the direction of the bottom of the liquid in such a
manner that the temperature drops to about -70.degree.C. in the
bottom portion. Advantageously the liquid is maintained for a short
distance below its upper surface at a temperature between about
0.degree. and 20.degree.C. Below this level the cooling of the
liquid is arranged in such a manner that the temperature drops to
-70.degree.C. in the bottom portion. However, any lower temperature
than this figure can also be utilized, depending upon the nature of
the liquid and the reagent being treated. For example, cryogenic
liquids such as liquid nitrogen which has a boiling point of
-143.degree.C., or liquid oxygen which has a boiling point of
-183.degree.C., may also be employed.
The desired temperature of the liquid column is achieved either by
use of a freezing mixture which surrounds the body of liquid or by
mechanical refrigeration to equivalent temperatures. For example,
the freezing mixture may be a combination of dry ice and acetone,
or of dry ice and methyl Cellosolve (diethylene glycol monomethyl
ether).
Advantageously the upper level of the refrigerated portion of the
liquid, which is maintained between about 0.degree.C. and
20.degree.C., comprises a zone extending not more than about 6
inches below the surface of the liquid. This provides a 6 inch fall
at a temperature above freezing and thus an opportunity for
formation of a truly spherical pellet.
In this way spherical drops are formed which freeze into beads as
they descend through the liquid column. The frozen beads collect on
the bottom and can be removed and freeze-dried to produce stable
dry spheres containing accurately measured quantities of desired
reagents. The frozen spheres are preferably collected in a wire
mesh basket and may be readily handled mechanically so that they
may be placed into any prechilled container, such as a test tube,
and freeze-dried in situ. Advantageously the frozen spheres are
stored under refrigeration at temperatures of -50.degree.C. or
lower to prevent crystal growth within the spheres, which might
cause them to become friable.
For purposes of freeze-drying, one or more spheres of selected
reagents are placed in a prechilled container and transferred
without warming to the prechilled shelves of a conventional
freeze-drying apparatus in which the drying takes place, for
example, at a starting temperature of -50.degree.C. and rising
during the drying to +37.degree.C. at the finish and at a pressure
not higher than about 100.mu. at the start and approaching 5.mu. at
the finish which is 18 hours to 24 hours later.
Where the reagent pellets are placed into a suitable test tube for
future use the test tube may then be capped utilizing a
moisture-proof closure and stored for an indefinite period. A
testing device of this kind is shown in FIG. 2 of the drawings.
As will be apparent from the drawings, the test device comprises a
tubular container having a transparent sidewall and bottom portion
adapted to receive the liquid to be tested and provided with a
moisture-proof closure. There is placed in the container at least
one reagent pellet prepared in accordance with the invention. The
liquid to be tested is applied to the pellet or pellets by opening
the closure and introducing a measured amount of the liquid by
means of a dropper.
It is apparent that the principles of the invention can be applied
not only to the preparation of analytical reagents but also to the
preparation of pharmaceutical dosage forms, particularly those
involving small dosages of the medicament involved.
In the field of immunology by the selection of appropriate
reagents, the test pellets can be used for performing any
immunological test in which two incompatible test reagents are
present in the same tube, such as, for example, the pregnancy test
described more fully below, and also test for blood group
substances in plasma and serum, blood group typing, and antigens
and antibodies of various kinds, including rheumatoid factor,
syphilis antigen, antistreptolysin O, infectious mononucleosis, and
other agglutination or precipitin tests. Moreover, in order to
demonstrate to a user of the test device what a proposed reaction
looks like, or as a control, a pellet of the substance being tested
for can be treated in a separate test alongside the actual specimen
to be tested, using two tubes, e.g., a freeze-dried pellet of known
pregnant urine.
DESCRIPTION OF THE PREFERRED EMBODIMENTS
The following examples are indicative of a presently preferred
embodiment of the invention but are not to be considered as
limiting the invention thereto.
The preparation of a set of test reagent pellets for the detection
of human chorionic gonadotropin in urine is disclosed in the
following examples:
EXAMPLE 1
Preparation of HCG Antiserum Pellets
The reagents are Sucrose 10.2 Gm. Sodium Chloride 0.765 Gm. Dibasic
Sodium Phosphate Heptahydrate 2.462 Gm. (Na.sub.2 HPO.sub.4
7H.sub.2 O) Monobasic Potassium Phosphate 0.489 Gm. (KH.sub.2
PO.sub.4) Distilled water, q.s. 170.0 ml. Anti-human chorionic
gonadotropin .sup.(1) .sup.(1) q.s. to yield sensitivity factor of
650 - 800 I.U. HCG/liter an 5, 5, 3-1, 2-0 reactions with urine at
0, 500, 750, and 1000 I.U./liter urine, respectively. A reaction
graded 5 is complete agglutination and 0 is complete
inhibition.
The above salts are dissolved in approximately 150 ml. water. The
pH of the resultant solution is adjusted to 7.2 (.+-. 0.05) with
0.1 N HCl or 0.1 N NaOH. The required amount of water is added to
bring the volume to 170 ml. Chill in an ice bath and add the exact
predetermined quantity of anti-HCG serum to yield the required
dilution. From this point on the solution is kept chilled in an ice
bath.
A clean 0.05 ml. microtiter dropping pipet delivery apparatus is
flushed out with this diluted antiserum by running an Auto analyzer
proportioning pump until one or 2 milliliters have been pumped,
taking care to remove any bubble in the delivery tube. Then the
pump is stopped and the microtiter delivery apparatus placed in
position in the freezing column. The pump is started and the
manufacture of the pellets is commenced.
When the pellets are removed from the freezing column, they are
stored under hexane in a closed container in either a dry-ice chest
or in a mechanical refrigerator maintained at -50.degree.C. to
-60.degree.C.
EXAMPLE 2
Preparation of Pellets of Sensitized Erythrocytes
A suspension of sheep erythrocytes is treated in conventional
manner with formalin and tannin and centrifuged and washed with a
phosphate sodium chloride buffer of pH 6.4 and then incorporated in
this buffer. To this mixture there is added an equal volume of a
solution of 50 I.U. HCG per ml. in a buffer of pH 6.4. The mixture
is stored for 48 hours at 37.degree.C., whereupon formaldehyde is
added until final concentration is obtained of 0.25% (wt/vol)
formaldehyde. Next this mixture is stored for 15 hours at
37.degree.C., whereupon the erythrocytes are again centrifuged,
washed with physiological salt solution, incorporated as 10% v/v
suspension in a physiological salt solution containing 0.1% of
bovine serumalbumin and stored until needed at 0.degree.-
4.degree.C. Thereafter the erythrocytes are centrifuged, washed
with physiological salt solution and freeze-dried in conventional
manner. Alternatively the formolized tanned cells are washed and
suspended in a phosphate sodium chloride buffer at pH 7.6. To this
mixture is added an equal volume of a solution of 50 I.U. HCG/ml.
This mixture is maintained at 56.degree.C. for 18 hours, then
washed and resuspended in 0.9% sodium chloride and mixed equal
parts with a solution of formaldehyde (1.5%) in 0.9% saline. This
mixture is stored at 2.degree. -8.degree.C. for about 1 week
whereupon the erythrocytes are again washed with 0.9% sodium
chloride and finally suspended to a concentration of 6.6% in a
mixture of pH 712 phosphate buffer containing sucrose 6% and bovine
serumalbumin 1.5%. This mixture is freeze-dried and held dry until
needed.
The sheep erythrocytes which have thus been sensitized by
chemically affixing HCG to their surfaces are suspended in a
mixture of buffer and a diluent such as sucrose and bovine
serumalbumin, so that there is contained in each 0.05 ml the
precise optimal quantity for a single HCG test.
Erythrocyte pellets are produced by reconstituting the previously
freeze-dried, sensitized erythrocytes to five-sixths of the
original volume, i.e., 12 ml of freeze-dried 6.67% suspension in
final suspension medium are reconstituted with 10 ml of distilled
water. This suspension is pumped to a microtiter dropping pipet.
Fine bore polyethylene tubing (I.D. = 0.023 inch) is used to
minimize erythrocytes settling and the pump is not turned off
during the process except momentarily.
The suspension is converted into calibrated drops as previously
described which are allowed to fall through a column of hexane
cooled by a mixture of dry ice-methyl Cellosolve, the temperature
of the hexane ranging from about ambient at its upper surface to
-70.degree.C. near the bottom of the column. The pellets are
collected and stored as in Example 1.
EXAMPLE 3
Preparation of Buffer Pellets
The reagents are: Sucrose 10.2 Gm. Sodium Chloride 0.765 Gm.
Dibasic Sodium Phosphate Heptahydrate 2.462 Gm. (Na.sub.2 HPO.sub.4
7H.sub.2 O) Monobasic Potassium Phosphate 0.489 Gm. (KH.sub.2
PO.sub.4) Disodium Ethylenediamine Tetraacetic acid 2.720 Gm.
Distilled Water, q. s. 170.0 ml. Aniline Blue-Black (Acid Black 1)
0.2 ml. Stock Solution
The above salts are dissolved in about 150 ml of water. The
solution is adjusted to pH 7.2 with 5.0 N NaOH, then q.s. with
water to 170 ml. Then add 0.2 ml of a stock dye solution consisting
of a 1.0 mg/ml solution (store dye solution in the refrigerator).
This solution need not be refrigerated during the production of the
pellets.
The buffer pellets are produced in an identical manner to that
described for the antiserum pellets. Subsequent to production, the
handling and storage are the same.
EXAMPLE 4
Method of Performing Pregnancy Test
One of each of the antiserum, HCG sensitized erythrocytes, and
buffer pellets are placed in the bottom of the test vial shown in
FIG. 2 of the drawings. There is introduced into the test vial by
means of a dropper a sample of the urine to be tested and
thereafter an additional volume of water is introduced equal to
about four times the amount of urine added. The test vial is then
recapped and shaken up and down for 30 seconds, after which it is
allowed to stand undisturbed for a period of 2 hours. The bottom of
the vial is visually inspected for a positive or negative
indication of agglutination. The formation of a donut-shaped ring
is a positive indication of pregnancy.
EXAMPLE 5
Application of the Pellet Principle
In a Diagnostic Enzyme Test
The principle of the kinetic U.V. test for the assay of serum
glutamate-pyruvate transaminase activity in serum (S.G.P.T.)
involves the following reactions:
1. Assay reaction
L-alanine + .alpha.-keto glutaric acid .sup.G.P.T. pyruvic acid +
L-glutamic acid
2. Indicator reaction
Pyruvic acid + NADH.sub.2 .sup.LDH L-lactic acid + NAD
In the foregoing equations, the abbreviations mean:
G.p.t. -- glutamate-pyruvate transaminase
Nadh.sub.2 -- nicotinamide-adenine-dinucleotide, reduced form
Nad -- nicotinamide-adenine-dinucleotide, oxidized form
Ldh -- lactic acid dehydrogenase
For each molecule pyruvic acid originating from reaction (1), one
molecule of NADH.sub.2 is oxidized to NAD. The decrease in optical
density is determined directly in U. V. at 334 nm in a 25.degree.C.
photometer cuvette.
a. Preparation of buffer-enzyme pellets
The following reagents solutions are prepared:
Solution 1: 250 ml 3 millimolar aqueous solution of reduced
nicotinamide-adenine-dinucleotide. The fresh solution is kept at
0.degree. - 4.degree.C. until needed.
Solution 2: 500 ml aqueous solution of lactic acid dehydrogenase,
having at least 180,000 I.U. LDH-activity per litre. The fresh
solution is kept at 0.degree. - 4.degree.C. until needed.
Solution 3: 1250 ml 0.2 molar aqueous solution of L-alanine.
Solution solutions 4: 3000 ml of an aqueous solution which is 5
millimolar in ethylenediamine tetraacetic acid and 50 millimolar in
triethanolamine. The pH of this solution has been adjusted to a pH
of 7.5.
The soutions 3 and 4 are thoroughly mixed and cooled to 0.degree.-
4.degree.C. Then the solutions 1 and 2 are added and the solution
is thoroughly stirred.
Buffer-enzyme pellets are prepared from the foregoing mixture as
described in Example 1. They are filled into small polyethylene
vials as shown in FIG. 2, each vial containing that number of
pellets corresponding with 0.5 ml of the buffered solution.
After lyophilization the vials are closed with a red screw cap.
b. Preparation of buffer-substrate pellets
The following reagent solutions are prepared:
Solution 5: 200 ml 0.2 molar aqueous sodium-.alpha.-keto glutarate.
The fresh solution is kept at 0.degree.- 4.degree.C. until
needed.
Solution 6: 800 ml of an aqueous solution having the composition of
solution 4.
Solution 6 is cooled to 0.degree. -4.degree.C. and then thoroughly
mixed with solution 5.
Buffer-substrate pellets of 0.1 ml of this mixed solution are
prepared according to Example 1. They are filled into small
polyethylene vials as shown in FIG. 2, each vial containing one
pellet. After lyophilization the vials are closed with blue screw
caps.
c. Performance of the kinetic U.V.-assay
To a vial prepared as described in this example under (a), 0.5 ml
of distilled water and 0.2 ml of the serum to be assayed are added
using Marburg pipettes. After shaking, the resulting solution is
brought quantitatively into a 25.degree.C. cuvette of an
"Eppendorf" spectrophotometer. Pre-incubation takes place for about
10 minutes. During this time the endogenous substrate in the sample
is being converted. Optical density is read until constant. Then a
blue-capped vial is opened and 0.1 ml distilled water is added with
a Marburg pipette. The clear solution is then brought
quantitatively into the cuvette and thoroughly mixed.
Optical density readings are made then every 30 seconds, and the
decrease is noted for at least 2 minutes. The values obtained are
averaged, and the S.G.P.T. activity of the sample is calculated
using the formula:
I.U. = .DELTA. O.D./min .times. 667 .mu. Mole .times.
min.sup.-.sup.1 .times. litre.sup.-.sup.1.
* * * * *